Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan.

Hoshi SL, Kondo M, Okubo I.

Vaccine. 2012 May 9;30(22):3320-8. doi: 10.1016/j.vaccine.2012.02.033. Epub 2012 Mar 3.

PMID:
22386745
2.

Economic evaluation of vaccination programme of 13-valent pneumococcal conjugate vaccine to the birth cohort in Japan.

Hoshi SL, Kondo M, Okubo I.

Vaccine. 2013 Jun 7;31(25):2762-71. doi: 10.1016/j.vaccine.2013.03.052. Epub 2013 Apr 13.

PMID:
23588088
3.

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.

Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS.

Vaccine. 2011 Sep 2;29(38):6686-94. doi: 10.1016/j.vaccine.2011.06.091. Epub 2011 Jul 13.

PMID:
21745516
5.

Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.

Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, Rodenburg GD, Hak E, Postma MJ.

BMJ. 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

6.

Economic evaluation of vaccination programme of mumps vaccine to the birth cohort in Japan.

Hoshi SL, Kondo M, Okubo I.

Vaccine. 2014 Jul 16;32(33):4189-97. doi: 10.1016/j.vaccine.2014.05.020. Epub 2014 Jun 9.

PMID:
24923640
7.

[Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].

Muciño-Ortega E, Mould-Quevedo JF, Farkouh R, Strutton D.

Value Health. 2011 Jul-Aug;14(5 Suppl 1):S65-70. doi: 10.1016/j.jval.2011.05.025. Spanish.

8.

Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina.

Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C.

Vaccine. 2011 Jul 12;29(31):4963-72. doi: 10.1016/j.vaccine.2011.04.111. Epub 2011 May 27.

PMID:
21621575
9.

Cost-effectiveness analysis of pneumococcal conjugate vaccine introduction in Paraguay.

Kieninger MP, Caballero EG, Sosa AA, Amarilla CT, Jáuregui B, Janusz CB, Clark AD, Castellanos RM.

Vaccine. 2015 May 7;33 Suppl 1:A143-53. doi: 10.1016/j.vaccine.2014.12.078.

PMID:
25919155
10.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
11.

Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.

Bergman A, Hjelmgren J, Ortqvist A, Wisløff T, Kristiansen IS, Högberg LD, Persson KM, Persson U.

Scand J Infect Dis. 2008;40(9):721-9. doi: 10.1080/00365540802014872.

PMID:
18712627
12.

Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.

Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Abo Freikha S, Hoestlandt C, Lara C, Hajjeh R, Munier A.

Vaccine. 2015 May 7;33 Suppl 1:A182-91. doi: 10.1016/j.vaccine.2014.12.044.

PMID:
25919159
13.

Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.

Melegaro A, Edmunds WJ.

Vaccine. 2004 Oct 22;22(31-32):4203-14.

PMID:
15474710
14.

Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.

Giglio ND, Cane AD, Micone P, Gentile A.

Vaccine. 2010 Mar 8;28(11):2302-10. doi: 10.1016/j.vaccine.2009.12.070. Epub 2010 Jan 9.

PMID:
20064478
15.

Impact of routine PCV7 (Prevenar) vaccination of infants on the clinical and economic burden of pneumococcal disease in Malaysia.

Aljunid S, Abuduxike G, Ahmed Z, Sulong S, Nur AM, Goh A.

BMC Infect Dis. 2011 Sep 21;11:248. doi: 10.1186/1471-2334-11-248.

16.

Economic evaluation of pneumococcal conjugate vaccination in The Gambia.

Kim SY, Lee G, Goldie SJ.

BMC Infect Dis. 2010 Sep 3;10:260. doi: 10.1186/1471-2334-10-260.

17.

Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.

Sohn HS, Suh DC, Jang E, Kwon JW.

J Manag Care Pharm. 2010 Jan-Feb;16(1):32-45.

18.

Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.

Wisløff T, Abrahamsen TG, Bergsaker MA, Løvoll Ø, Møller P, Pedersen MK, Kristiansen IS.

Vaccine. 2006 Jul 17;24(29-30):5690-9. Epub 2006 May 5.

PMID:
16735083
19.

Cost-effectiveness of pneumococcal conjugate vaccines of 7, 10, and 13 valences in Colombian children.

Castañeda-Orjuela C, Alvis-Guzmán N, Velandia-González M, De la Hoz-Restrepo F.

Vaccine. 2012 Mar 2;30(11):1936-43. doi: 10.1016/j.vaccine.2012.01.031. Epub 2012 Jan 21.

PMID:
22266291
20.
Items per page

Supplemental Content

Write to the Help Desk